Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium

Presentations to Explore Paxalisib’s Differentiated Tumor and Immune Reprogramming Activity SYDNEY, Nov.…

BingX Wraps Up TOKEN2049 Singapore 2026 as Title Sponsor, Showcasing "Building the Future of Trading" Vision

PANAMA CITY, Nov. 2, 2026 /PRNewswire/ — BingX, the world’s leading multi-asset trading…

ECARX Signs MoU with Arm to advance next-generation high-performance AI computing across industry applications

MoU establishes framework to explore advanced solution development, including joint R&D and…

InventisBio Announces Topline Results of a Phase III Study of Nomelcitinib (TYK2 Inhibitor), Demonstrating Promising Efficacy and Safety in Patients with Moderate to Severe Plaque Psoriasis.

SHANGHAI, Nov. 2, 2026 /PRNewswire/ — InventisBio Co., Ltd. today announced that…

LianLian Global and Cobre Collaborate to Streamline China-Latin America Payments

HONG KONG, Nov. 2, 2026 /PRNewswire/ — LianLian Global, the cross-border payment…

FREELANDER Deepens Its Middle East Roll-out and Makes Morocco Its First Step into Africa

Full-scale entry into the Middle East is set for the first half…

Xinhua Silk Road: 2026 International Exchange on Women and Children's Health held in Boao, Hainan

BEIJING, Nov. 2, 2026 /PRNewswire/ — The 2026 International Exchange on Women…

Trade Your View Before the IPO: Vantage Spotlights its Pre-IPO CFD Offering

Vantage highlights how eligible clients can express long or short views before…